Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/21/2025

Statin Therapy Guidelines

Non-Fasting Lipid Profiles

  • The American College of Cardiology recommends that non-fasting lipid profiles are acceptable for determining statin therapy need, as they provide acceptably accurate measures for cardiovascular risk calculation and treatment decisions 1, 2
  • Total cholesterol and HDL-C levels differ minimally between fasting and non-fasting states, with non-fasting LDL-C being approximately 10% lower and triglycerides up to 20% higher compared to fasting measures 1
  • The small variance in LDL-C is unlikely to affect risk classification or therapeutic decisions, as risk calculation requires only total cholesterol and HDL-C levels, which are reliable in non-fasting samples 1, 2

Indications for Fasting Lipid Panels

  • The American College of Cardiology suggests ordering a fasting lipid panel if non-fasting triglycerides are ≥400 mg/dL, as the Friedewald equation for calculating LDL-C becomes inaccurate at this level 1, 2, 3
  • A fasting profile is reasonable for initial evaluation in patients with a family history of premature ASCVD or genetic hyperlipidemia 3, 4

Statin Therapy Decisions

  • The American College of Cardiology recommends initiating high-intensity statin therapy in patients with clinical ASCVD, LDL-C ≥190 mg/dL, or diabetes mellitus (age 40-75 years) 5, 6
  • For patients without these conditions, calculate 10-year ASCVD risk using total cholesterol and HDL-C from the non-fasting panel, and initiate moderate-to-high intensity statin therapy if the risk is ≥7.5-10% 5, 6
  • For patients >75 years with clinical ASCVD, moderate-intensity statin therapy should be considered, as high-intensity statin therapy showed no clear additional ASCVD event reduction in this age group 5, 6

Statin Intensity and Monitoring

  • The American College of Cardiology recommends high-intensity statins (reduce LDL-C ≥50%) for patients with clinical ASCVD or LDL-C ≥190 mg/dL, and moderate-intensity statins (reduce LDL-C 30-50%) for patients with diabetes or 10-year ASCVD risk ≥7.5-10% 5, 6
  • Obtain a lipid panel 4-12 weeks after statin initiation to assess adherence and therapeutic response, without requiring fasting unless triglycerides were initially ≥400 mg/dL 1, 2, 6

REFERENCES